SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS
申请人:VANDERBILT UNIVERSITY
公开号:US20150336925A1
公开(公告)日:2015-11-26
The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors
申请人:VANDERBILT UNIVERSITY
公开号:US10093640B2
公开(公告)日:2018-10-09
The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
Chemical entities that kill senescent cells for use in treating age-related disease
申请人:Unity Biotechnology, Inc.
公开号:US10195213B2
公开(公告)日:2019-02-05
Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.
Substituted benzofuran, benzothiophene and indole Mcl-1 inhibitors
申请人:Vanderbilt University
公开号:US10844032B2
公开(公告)日:2020-11-24
The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
Heterocyclic degronimers for target protein degradation
申请人:C4 Therapeutics, Inc.
公开号:US10905768B1
公开(公告)日:2021-02-02
This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.